RxDoctor Payments Data

Christopher Walsh, MD

Internal Medicine · Arlington, VANPI 1699788190

Payments from drug & device makers

$415in general payments, 2019–2025

Across 16 payments — averaging $25.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$163
  • Lilly USA, LLC$55
  • Amarin Pharma, Inc.$44
  • Pfizer$39
  • Merck$29
  • Dynavax Technologies Corporation$25
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$415100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$415 in reported general payments places this provider in the 65th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$239,281
Medicare patients
672
Services billed
2,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin60$92,338
EliquisApixaban78$87,508
NuplazidPimavanserin Tartrate12$53,806
OzempicSemaglutide25$46,813
JanuviaSitagliptin Phosphate17$22,728
XareltoRivaroxaban13$18,242
FarxigaDapagliflozin Propanediol18$16,186
Atorvastatin Calcium751$7,869
LumiganBimatoprost20$6,789
SynthroidLevothyroxine Sodium52$5,966
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,811
Dexlansoprazole DrDexlansoprazole13$3,777
MyrbetriqMirabegron11$3,451
Fluticasone Propionate68$2,938
Rosuvastatin Calcium131$2,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$87,50878 claims
Novo NordiskOzempic$163$46,81325 claims
MerckJanuvia$29$22,72817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →